Format

Send to

Choose Destination
J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.

Author information

1
1 The Alfred Hospital and Monash University, Melbourne, VIC, Australia.
2
2 Vanderbilt-Ingram Cancer Center, Nashville, TN.
3
3 University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA.
4
4 University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
5
5 University of Kansas Medical Center, Kansas City, KS.
6
6 University of Washington, Seattle, WA.
7
7 Fred Hutchinson Cancer Research Center, Seattle, WA.
8
8 Calvary Mater Hospital Newcastle, Waratah, NSW, Australia.
9
9 University of Newcastle, Callaghan, NSW, Australia.
10
10 Weill Cornell Medical College, New York, NY.
11
11 AbbVie, North Chicago, IL.
12
12 Ain Shams University, Cairo, Egypt.
13
13 Genentech, South San Francisco, CA.

Abstract

PURPOSE:

Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study evaluated the safety and preliminary efficacy of venetoclax, a selective B-cell leukemia/lymphoma-2 inhibitor, together with low-dose cytarabine (LDAC) in older adults with AML.

PATIENTS AND METHODS:

Adults 60 years or older with previously untreated AML ineligible for intensive chemotherapy were enrolled. Prior treatment of myelodysplastic syndrome, including hypomethylating agents (HMA), was permitted. Eighty-two patients were treated at the recommended phase II dose: venetoclax 600 mg per day orally in 28-day cycles, with LDAC (20 mg/m2 per day) administered subcutaneously on days 1 to 10. Key end points were tolerability, safety, response rates, duration of response (DOR), and overall survival (OS).

RESULTS:

Median age was 74 years (range, 63 to 90 years), 49% had secondary AML, 29% had prior HMA treatment, and 32% had poor-risk cytogenetic features. Common grade 3 or greater adverse events were febrile neutropenia (42%), thrombocytopenia (38%), and WBC count decreased (34%). Early (30-day) mortality was 6%. Fifty-four percent achieved complete remission (CR)/CR with incomplete blood count recovery (median time to first response, 1.4 months). The median OS was 10.1 months (95% CI, 5.7 to 14.2), and median DOR was 8.1 months (95% CI, 5.3 to 14.9 months). Among patients without prior HMA exposure, CR/CR with incomplete blood count recovery was achieved in 62%, median DOR was 14.8 months (95% CI, 5.5 months to not reached), and median OS was 13.5 months (95% CI, 7.0 to 18.4 months).

CONCLUSION:

Venetoclax plus LDAC has a manageable safety profile, producing rapid and durable remissions in older adults with AML ineligible for intensive chemotherapy. High remission rate and low early mortality combined with rapid and durable remission make venetoclax and LDAC an attractive and novel treatment for older adults not suitable for intensive chemotherapy.

PMID:
30892988
PMCID:
PMC6524989
[Available on 2020-05-20]
DOI:
10.1200/JCO.18.01600

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center